MetaCap

Arcutis Biotherapeutics (ARQT) vs Tango Therapeutics (TNGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tango Therapeutics (TNGX) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 116.7% versus a loss of 10.6%. Over five years, TNGX leads with a +110.0% price change compared with +58.1% for ARQT. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.33 billion), about 1.1 times the size, while Arcutis Biotherapeutics is growing revenue faster (+91.3% vs +48.3%).

Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -162.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARQT-10.61%TNGX+116.65%
+241%+97%-47%
Nov 21, 20251 yearNov 20, 2026
ARQT+44.91%TNGX+81.54%
+176%+36%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARQT versus TNGX key metrics
MetricARQTTNGX
Share price$26.36$21.73
Market cap$3.33B$3.68B
1-day change-2.98%-4.32%
YTD return-9.23%+145.26%
1-year return-10.61%+116.65%
5-year return+58.13%+109.95%
P/E ratio (TTM)119.82—
Forward P/E24.09—
EPS (TTM)$0.22$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$376.07M$62.38M
Revenue growth (YoY)+91.34%+48.29%
Net income (latest FY)$-16.14M$-101.59M
Gross margin90.24%—
Operating margin-3.25%-178.39%
Net margin-4.29%-162.85%
52-week high$34.80$34.39
52-week low$19.30$8.30
Distance from 52-week high-24.25%-36.81%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.19%+116.29%
Average volume2.58M3.41M
Shares outstanding126.46M169.46M
Employees354137
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TNGX has outperformed ARQT by 127.3 percentage points over the past year.
  • Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
  • Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +48.29%).

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

About Tango Therapeutics

TNGX stock →

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees

ARQT vs TNGX FAQ

Which is bigger, Arcutis Biotherapeutics or Tango Therapeutics?

Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.33B for Arcutis Biotherapeutics (ARQT).

Which stock has performed better over the past year, ARQT or TNGX?

TNGX returned +116.65% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.

Are Arcutis Biotherapeutics and Tango Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons